ImmunityBio Shares Rise Following Market Endorsement
The pharmaceutical company saw stock gains after receiving a positive speculative investment recommendation.
Updated on Oct. 27, 2026 in Cancer
Live Poll
Is now a good time to consider speculative investments in individual biotech stocks?
ImmunityBio shares increased nearly 1% overnight following a speculative investment recommendation from Jim Cramer. The company continues to advance its bladder cancer treatment portfolio through recent clinical data and regulatory progress.
Why it matters
The company aims to expand the clinical use of its Anktiva drug for bladder cancer treatment. This move aligns with broader efforts to improve survival rates while minimizing the need for invasive bladder-removal surgeries.
A 366-patient trial study revealed a 71% complete response rate for the Anktiva treatment. Among responders, 84% survived three years without requiring bladder-removal surgery, with some treatment effects lasting beyond 53 months.
The players
ImmunityBio
This biotechnology company focuses on developing immunotherapies to treat cancer and infectious diseases.
Jim Cramer
He is a prominent television host and financial commentator known for providing stock market analysis.
AbbVie
This biopharmaceutical company engages in the discovery and development of advanced therapies for complex health conditions.
Eli Lilly
This global pharmaceutical corporation develops and markets a wide range of human health medicines.
Viatris
This global healthcare company focuses on providing access to medicines and expanding into various therapeutic sectors.
The details
ImmunityBio shares closed Monday at $7.81, reflecting a 294% increase year-to-date. The company is currently finalizing data from a trial comparing Anktiva plus BCG against BCG alone in non-muscle invasive bladder cancer patients.
Timeline
August 2026: Eli Lilly agreed to acquire Merida Biosciences.
September 2026: AbbVie completed the acquisition of Apogee Therapeutics.
October 2026: The FDA expanded Anktiva approval and Viatris announced an acquisition.
November 2026: ImmunityBio expects results from a 366-patient trial.
Q4 2026: ImmunityBio plans to submit an application to expand FDA approval.
Health Landscape
The expansion of the FDA approval of Anktiva plus BCG marks a pivotal regulatory milestone for the manufacturer following the October 2026 decision. This shift builds upon the clinical path established by existing immunotherapy protocols for non-muscle invasive bladder cancer.
The clinical progress of Anktiva offers potential new treatment pathways for patients managing non-muscle invasive bladder cancer. These developments could eventually provide options that preserve bladder function and improve long-term survival outcomes for patients.
The takeaway
Advancements in immunotherapy trials for bladder cancer are increasingly focusing on organ-sparing treatments. Patients and investors should monitor upcoming trial results as these outcomes directly influence future regulatory submissions and therapeutic availability.
What happens next
ImmunityBio expects to release results from its 366-patient clinical trial in November 2026 and plans to submit an application to expand FDA approval during the fourth quarter of 2026.
Further reading
For more information on current treatment standards and research, visit the Cancer section.
Live Poll
Is now a good time to consider speculative investments in individual biotech stocks?
